Barclays PLC Grows Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT)

Barclays PLC raised its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 329.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 165,765 shares of the company's stock after acquiring an additional 127,156 shares during the period. Barclays PLC owned about 0.16% of MaxCyte worth $645,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of MXCT. State Street Corp increased its position in shares of MaxCyte by 5.1% during the third quarter. State Street Corp now owns 2,269,135 shares of the company's stock valued at $8,827,000 after acquiring an additional 111,066 shares during the last quarter. Chevy Chase Trust Holdings LLC grew its stake in MaxCyte by 0.7% in the 3rd quarter. Chevy Chase Trust Holdings LLC now owns 1,332,048 shares of the company's stock valued at $5,182,000 after purchasing an additional 9,488 shares during the period. ArrowMark Colorado Holdings LLC increased its position in shares of MaxCyte by 13.8% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company's stock valued at $5,426,000 after purchasing an additional 169,250 shares during the last quarter. Verition Fund Management LLC raised its stake in shares of MaxCyte by 39.5% during the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company's stock worth $83,000 after purchasing an additional 6,045 shares during the period. Finally, Mudita Advisors LLP boosted its holdings in shares of MaxCyte by 5.6% in the 3rd quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company's stock worth $12,267,000 after buying an additional 167,101 shares during the last quarter. 68.81% of the stock is owned by hedge funds and other institutional investors.

MaxCyte Stock Down 0.2 %

NASDAQ MXCT traded down $0.01 during trading hours on Thursday, reaching $4.15. 438,072 shares of the company were exchanged, compared to its average volume of 530,714. The stock has a market capitalization of $438.62 million, a P/E ratio of -12.21 and a beta of 1.37. MaxCyte, Inc. has a 1 year low of $3.16 and a 1 year high of $5.55. The business's 50 day simple moving average is $3.79 and its 200-day simple moving average is $4.01.

MaxCyte (NASDAQ:MXCT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. The business had revenue of $8.16 million for the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. During the same quarter in the prior year, the business earned ($0.11) earnings per share. As a group, sell-side analysts anticipate that MaxCyte, Inc. will post -0.42 earnings per share for the current year.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.